Literature DB >> 2849603

Effects of fleroxacin on HeLa cell functions and topoisomerase II.

Y Oomori1, T Yasue, H Aoyama, K Hirai, S Suzue, T Yokota.   

Abstract

The effects of fleroxacin and other new 4-quinolones on cellular functions and topoisomerase II of HeLa cells were investigated. The potency of cytotoxicity increased in the order fleroxacin less than nalidixic acid less than ofloxacin less than norfloxacin less than ciprofloxacin. The cytotoxicity was well correlated with inhibitory effects of 4-quinolones on topoisomerase II. However, the cytotoxicity did not correlate with antibacterial activity, and cytotoxicity was observed only at greater than 100-fold higher concentrations than the minimum inhibitory concentrations of new 4-quinolones for Enterobacteriaceae. Judging from the serum levels attainable after oral administration, new 4-quinolones, especially fleroxacin, will have little effect on topoisomerase in eukaryotic cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849603     DOI: 10.1093/jac/22.supplement_d.91

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Authors:  J F Barrett; T D Gootz; P R McGuirk; C A Farrell; S A Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

Authors:  K Hoshino; K Sato; K Akahane; A Yoshida; I Hayakawa; M Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 3.  Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.

Authors:  T D Gootz; J F Barrett; J A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

4.  Ciprofloxacin-induced antibacterial activity is reversed by vitamin E and vitamin C.

Authors:  Majed M Masadeh; Nizar M Mhaidat; Karem H Alzoubi; Sayer I Al-Azzam; Ashraf I Shaweesh
Journal:  Curr Microbiol       Date:  2012-02-18       Impact factor: 2.188

Review 5.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.

Authors:  A H Corbett; P Guerry; P Pflieger; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.

Authors:  M Hosaka; T Yasue; H Fukuda; H Tomizawa; H Aoyama; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.

Authors:  S H Elsea; P R McGuirk; T D Gootz; M Moynihan; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

9.  Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.

Authors:  S J Froelich-Ammon; P R McGuirk; T D Gootz; M R Jefson; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2.

Authors:  A Pessina; E Mineo; L Gribaldo; M G Neri
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.